Abstract Number: 2264 • ACR Convergence 2022
Dysregulated Interferon Gamma Signals Promote Systemic Autoimmunity in STAT1 Gain of Function Syndrome
Background/Purpose: Heterozygous gain-of-function mutations in STAT1 promote a complex disorder of immune dysregulation including chronic mucocutaneous candidiasis (CMC) and systemic autoimmunity. However, given widespread expression…Abstract Number: 0644 • ACR Convergence 2022
Long-lived Plasma Cells in the Lupus Bone Marrow Are Imprinted by Interferon
Background/Purpose: Systemic lupus erythematous (SLE) is a complex autoimmune disorder with heterogeneous disease presentation and a multi-pronged pathogenesis. Although autoreactive plasma cells (PC) play a…Abstract Number: 1664 • ACR Convergence 2022
TRIM21 as a Regulator of UVB-Driven IFN Responses in Lupus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) experience photosensitivity where exposure to ultraviolet light B (UVB) drives lupus flares and systemic symptoms. Although the mechanisms…Abstract Number: 2267 • ACR Convergence 2022
Plasmacytoid Dendritic Cells Are Not Major Producers of Type 1 Interferons in Cutaneous Lupus
Background/Purpose: Type 1 interferons (IFN-1) are major drivers of disease activity in systemic (SLE) and cutaneous lupus erythematosus (CLE). Plasmacytoid dendritic cells (pDCs) are the…Abstract Number: L20 • ACR Convergence 2021
Efficacy of Emapalumab, an Anti-IFNγ Antibody in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA) Who Had Failed High-Dose Glucocorticoids (GCs)
Background/Purpose: MAS is a life-threatening complication of rheumatic diseases, occurring most frequently in sJIA. The mainstay of MAS treatment is high dose GCs; however, GCs…Abstract Number: 0501 • ACR Convergence 2021
Immunogenicity of a Single Dose of Covid-19 Vaccination in Patients with Systemic Sclerosis with or Without Immunosupression
Background/Purpose: Systemic Sclerosis (SSc) is a rare connective tissue disease with multi-systemic involvement, which at times requires the use of immunosuppressive medication. None of the…Abstract Number: 1494 • ACR Convergence 2021
Functional Effects of a Lupus-associated PRKG1 Variant on the RhoA-ROCK Pathway and Response to Type I Interferon
Background/Purpose: Interferon (IFN)-α contributes to susceptibility and severe manifestations in systemic lupus erythematosus (SLE). The PRKG1 rs7897633 variant has been previously identified as the top…Abstract Number: 0528 • ACR Convergence 2021
Interferon Pathway Lupus Risk Alleles Modulate Risk of Death from Acute COVID-19
Background/Purpose: Type I interferon (IFN) is critical in our defense against viral infections. Increased type I IFN pathway activation is a genetic risk factor for…Abstract Number: 1495 • ACR Convergence 2021
Multiplexed Profiling of Treatment Naïve Cutaneous Lupus Skin Stratified by Patient Response to Antimalarials
Background/Purpose: Lupus erythematous (LE) is a systemic autoimmune disease with a variety of cutaneous manifestations. Antimalarials are first-line systemic therapy, yet not all patients respond…Abstract Number: 0705 • ACR Convergence 2021
Mitochondrial Calcification-Induced Inflammation in Human Skeletal Muscle and Immune Cells
Background/Purpose: Children with juvenile dermatomyositis (JDM) have decreased autophagy, as also confirmed by our RNA seq data in JDM muscle, which may contribute to accumulation…Abstract Number: 1504 • ACR Convergence 2021
Association Between Anti-RNP Antibodies and Interferon Gene Expression but Not Complement Consumption in SLE
Background/Purpose: Anti-nuclear antibodies are important serologic features of SLE and facilitate diagnosis. Anti-double stranded DNA (dsDNA) antibodies are routinely monitored for disease prognosis and are…Abstract Number: 0874 • ACR Convergence 2021
Serum Galectin-9 and CXCL-10 but Not Their Urinary Levels Reflect Lupus Activity
Background/Purpose: SLE is characterized by increased type I IFN signature in the blood and immune cells. Traditionally, type I IFN signature is measured by gene…Abstract Number: 1618 • ACR Convergence 2021
Disease Flares in CANDLE/PRAAS with Dose Reductions of Baricitinib
Background/Purpose: Patients with chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures /proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS) respond to treatment with baricitinib but require higher exposure…Abstract Number: 0961 • ACR Convergence 2021
Proteomic Profiling of MIS-C Patients Reveals Heterogeneity Relating to Interferon Gamma Dysregulation and Vascular Endothelial Dysfunction
Background/Purpose: Multi-system Inflammatory Syndrome in Children (MIS-C) is a major complication of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic in pediatric patients. Children…Abstract Number: 1643 • ACR Convergence 2021
Increased Incidence of Pediatric SLE and Other Interferon Activated Diseases During COVID-19 Pandemic
Background/Purpose: COVID-19, as a member of the Coronavirus family, has been described to trigger host immune response via type I interferon (IFN) signaling pathways with…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 12
- Next Page »